• US therapeutic: $534M (+9% QoQ*, +24% YoY†) • US cosmetic: $356M (-3% QoQ*, +50% YoY†) -- US total: $880M (61% therapeutic; 39% cosmetic) was 75% of worldwide total
• Ex-US therapeutic: $111M (-1 QoQ*, +14% YoY†) • Ex-US cosmetic: $189M (-13% QoQ*, +18% YoY†) -- Ex-US total: $300M (37% therapeutic; 63% cosmetic) was 25% of worldwide total
*Botox sales are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.
†YoY growth rates are exaggerated due to the effect of the pandemic in 2020.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.